Wednesday, January 11, 2023 11:01:11 AM
If the FDA followed that line of analysis, then our competition Pfizer would be long gone along with Moderna and the rest of the real felons who have supported the scam jabs would be doing hard time. They avoided leronlimab, ivermectin, HCL because they work and EUA could not have been given if any product was available that works. That's the rule.
Seems common sense did prevail in some countries like Sweden, India, Russia, etc.
Those that followed the FDA/CDC didn't fair to well which is why I am alive and well because I used some good ole Scandinavian common sense not to take an experiment that has not been tested, fully published, and peer reviewed.
https://nypost.com/2022/05/06/sweden-saw-fewer-covid-19-deaths-than-majority-of-europe/
A big thanks to KarmeemyBad and sidekick Nada for taking advantage of the corruption and getting caught in a tangled mess that will probably give them some easy time in the can, if that, as they know too much and deals are always cut. Plus Kelly and Nada are patent holders so they will win in the end. Leronlimab is real science and now with real leadership and a super solid board and team doing the right things. The AmarX deal is ongoing... behind the scenes good things are working. Watch and wait. Meanwhile I will buy some more. $CYDY$ is the future. Go Cyrus
Phuzzy Pfizer couldn't get a real license to sell lemonade were the rules applied as written.
Seems common sense did prevail in some countries like Sweden, India, Russia, etc.
Those that followed the FDA/CDC didn't fair to well which is why I am alive and well because I used some good ole Scandinavian common sense not to take an experiment that has not been tested, fully published, and peer reviewed.
https://nypost.com/2022/05/06/sweden-saw-fewer-covid-19-deaths-than-majority-of-europe/
A big thanks to KarmeemyBad and sidekick Nada for taking advantage of the corruption and getting caught in a tangled mess that will probably give them some easy time in the can, if that, as they know too much and deals are always cut. Plus Kelly and Nada are patent holders so they will win in the end. Leronlimab is real science and now with real leadership and a super solid board and team doing the right things. The AmarX deal is ongoing... behind the scenes good things are working. Watch and wait. Meanwhile I will buy some more. $CYDY$ is the future. Go Cyrus
Phuzzy Pfizer couldn't get a real license to sell lemonade were the rules applied as written.
Bullish
Recent CYDY News
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
